CN116139060B - Composition with anti-inflammatory and anti-aging effects and preparation method and application thereof - Google Patents
Composition with anti-inflammatory and anti-aging effects and preparation method and application thereof Download PDFInfo
- Publication number
- CN116139060B CN116139060B CN202310196679.5A CN202310196679A CN116139060B CN 116139060 B CN116139060 B CN 116139060B CN 202310196679 A CN202310196679 A CN 202310196679A CN 116139060 B CN116139060 B CN 116139060B
- Authority
- CN
- China
- Prior art keywords
- extract
- composition
- parts
- weight
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 27
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 64
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims abstract description 22
- 240000005125 Myrtus communis Species 0.000 claims abstract description 21
- 235000013418 Myrtus communis Nutrition 0.000 claims abstract description 21
- 240000005026 Aframomum daniellii Species 0.000 claims abstract description 15
- 239000001914 daemonorops spp. extract Substances 0.000 claims abstract description 14
- 239000001567 elettaria cardamomum seed Substances 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 240000006927 Foeniculum vulgare Species 0.000 claims abstract 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 14
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 14
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 14
- 229960000458 allantoin Drugs 0.000 claims description 14
- 238000000855 fermentation Methods 0.000 claims description 14
- 230000004151 fermentation Effects 0.000 claims description 14
- 229920002674 hyaluronan Polymers 0.000 claims description 14
- 229960003160 hyaluronic acid Drugs 0.000 claims description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- 239000003906 humectant Substances 0.000 claims description 12
- 239000003381 stabilizer Substances 0.000 claims description 12
- 239000002562 thickening agent Substances 0.000 claims description 12
- 241000590031 Alteromonas Species 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 244000075255 Monodora myristica Species 0.000 claims description 6
- 235000015885 Monodora myristica Nutrition 0.000 claims description 6
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- 229940048053 acrylate Drugs 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229940047670 sodium acrylate Drugs 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 abstract description 14
- 230000037393 skin firmness Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 55
- 238000012360 testing method Methods 0.000 description 44
- 241000212314 Foeniculum Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000839 emulsion Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 206010015150 Erythema Diseases 0.000 description 10
- 230000008439 repair process Effects 0.000 description 8
- 230000001815 facial effect Effects 0.000 description 7
- 230000036572 transepidermal water loss Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000000245 forearm Anatomy 0.000 description 5
- 230000008591 skin barrier function Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000001054 red pigment Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 240000004824 Trimezia steyermarkii Species 0.000 description 2
- -1 acrylic ester Chemical class 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010523 cascade reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000009136 dragon's blood Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 230000003960 inflammatory cascade Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000037070 skin defense Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 244000227206 Aframomum melegueta Species 0.000 description 1
- 235000015752 Aframomum melegueta Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The application relates to a composition with anti-inflammatory and anti-aging effects, and a preparation method and application thereof, and belongs to the technical field of cosmetics. The composition provided by the application comprises the following components in parts by weight: 0.0005 to 0.015 part of dragon's blood extract, 0.0005 to 0.01 part of fennel myrtle leaf extract and 0.0004 to 0.008 part of african cardamom seed extract. The main functional components of the composition are the kylin extract, the fennel myrtle leaf extract and the African cardamom seed extract, and the three main functional components are compounded, so that the composition has a synergistic effect, can efficiently and quickly remove the redness and the wrinkle of the face, improves the skin firmness and reduces the sensitivity, and has a good application prospect in the field of cosmetics.
Description
Technical Field
The application belongs to the technical field of cosmetics, and particularly relates to a composition with anti-inflammatory and anti-aging effects, and a preparation method and application thereof.
Background
The existing products of anti-inflammatory repair on the market contain more medicinal components and have the danger of medicament dependence; many skin care products with anti-inflammatory and repairing effects are declared on the market, but the products with exaggerated declared effects as selling points are quite many, in fact, the anti-inflammatory and repairing effects are not obvious or slow, even chemical components which can cause secondary damage to the skin are added, and the requirements of consumers cannot be met.
Thus, there is an urgent need to develop a composition having mild and efficient anti-inflammatory and anti-aging properties.
Disclosure of Invention
The application aims to overcome the defects of the prior art and provide a composition with mild and efficient anti-inflammatory and anti-aging properties, which can not only improve skin firmness but also reduce skin sensitivity.
In order to achieve the above purpose, the technical scheme adopted by the application is as follows:
in a first aspect, the application provides a composition with anti-inflammatory and anti-aging effects, comprising the following components in parts by weight: 0.0005 to 0.015 part of dragon's blood extract, 0.0005 to 0.01 part of fennel myrtle leaf extract and 0.0004 to 0.008 part of african cardamom seed extract.
The inventor researches of the application find that the combination of the extract of the kylin, the extract of the fennel myrtle leaves and the extract of the aframomum melegueta seeds in a specific proportion can stimulate the expression of anti-inflammatory factors IL-10 and TGF-beta, promote the generation of inflammatory fading medium SPM, reduce sebum secretion and sebaceous gland volume, inhibit inflammatory cascade reaction, simultaneously enable key fibrous networks to be synthesized again (collagen IV, collagen III, fibronectin and integrin 4 molecular synthesis), repair dermis epidermis connection layers, help maintain the optimal skin defense system, strengthen skin barrier function and stimulate skin repair capability, promote keratinocyte renewal, and enable the composition to have remarkable effects of improving skin redness and reducing wrinkles. In addition, the sources of the dragon's blood extract, the fennel myrtle leaf extract and the African cardamom seed extract adopted by the application are all natural plant extract raw materials, so that the safety is high, and the skin dependence can not be generated.
As a preferred embodiment of the composition according to the application, the composition comprises the following components in parts by weight: 0.007 to 0.013 part of dragon's blood extract, 0.005 to 0.008 part of fennel myrtle leaf extract and 0.0012 to 0.0028 part of African cardamom seed extract.
The inventor researches and discovers that the extract of the dragon's blood, the extract of the fennel myrtle leaf and the extract of the african cardamom seed have the effects of better enhancing the skin barrier function and stimulating the skin repair, and can more effectively and rapidly improve the skin redness and reduce the wrinkles in the range of the weight parts.
As a preferred embodiment of the composition according to the application, the composition further comprises the following components in parts by weight: 0.01 to 1 part of hydrolyzed hyaluronic acid, 0.03 to 0.09 part of sodium hyaluronate, 0.0006 to 0.003 part of alteromonas fermentation product extract and 0.1 to 0.3 part of allantoin.
The inventor researches and discovers that the application can further improve the renewal of skin keratinocytes and the mobility of fibroblasts, better improve the effect of skin redness, further reduce the sensibility of the skin and improve the tightening degree of the skin by combining the main functional components of the kylin extract, the fennel myrtle leaf extract and the African cardamom seed extract and simultaneously adding the compounded hydrolyzed hyaluronic acid, the sodium hyaluronate, the colloidal unit cell fermentation product extract and the allantoin in a specific ratio.
As a preferred embodiment of the composition according to the application, the composition comprises the following components in parts by weight: 0.007 to 0.013 part of dragon's blood extract, 0.005 to 0.008 part of fennel myrtle leaf extract, 0.0012 to 0.0028 part of African cardamom seed extract, 0.3 to 0.8 part of hydrolyzed hyaluronic acid, 0.04 to 0.08 part of sodium hyaluronate, 0.0015 to 0.0024 part of alteromonas fermentation product extract and 0.15 to 0.25 part of allantoin.
The inventor of the present application has found that the composition prepared by using the components in the above weight part range can improve the property of improving skin redness and skin firmness, and has better anti-inflammatory and anti-aging properties.
As a preferred embodiment of the composition according to the application, the composition comprises the following components in parts by weight: 0.01 part of dragon's blood extract, 0.007 part of fennel myrtle leaf extract, 0.002 part of African cardamom seed extract, 0.5 part of hydrolyzed hyaluronic acid, 0.06 part of sodium hyaluronate, 0.0021 part of alteromonas fermentation product extract and 0.2 part of allantoin.
The inventor of the present application has found that the composition can have optimal anti-inflammatory and anti-aging properties by using the above components in parts by weight, and can more rapidly and efficiently improve skin redness and improve skin firmness.
As a preferred embodiment of the composition of the application, the composition further comprises the following components in parts by weight: 0.25 to 1.8 parts of thickening agent, 2.6686 to 25.472 parts of humectant, 0.591 to 4.005 parts of antioxidant and 0.01 to 1 part of stabilizer.
The inventor of the application researches and discovers that the thickener, the humectant, the antioxidant and the stabilizer are adopted as auxiliary agents to be combined with the extract of the dragon's blood, the extract of the fennel and myrtle leaves and the extract of the African cardamom seeds, and meanwhile, the hydrolyzed hyaluronic acid, the sodium hyaluronate, the extract of the alteromonas fermentation product and the allantoin are added, so that the prepared composition has higher anti-inflammatory and anti-aging effects.
As a preferred embodiment of the composition of the present application, the thickener is 0.5 to 1.1 parts by weight, the humectant is 6.9288 to 12.1152 parts by weight, the antioxidant is 1.323 to 2.289 parts by weight, and the stabilizer is 0.03 to 0.07 parts by weight.
The inventor of the present application has found that the above auxiliary agent in the weight portion can make the anti-inflammatory and anti-aging effects of the prepared composition better.
As a preferred embodiment of the composition of the present application, the composition comprises at least one of the following (I) to (IV):
the thickening agent is at least one selected from acrylic ester/C10-30 alkanol acrylic ester cross-linked polymer, acrylic ester copolymer sodium and lecithin;
(II) the humectant is at least one of glycerolyether-26, glycerin, butanediol and ethylhexyl glycerin;
(III) the antioxidant is at least one selected from the group consisting of p-hydroxyacetophenone, propylene glycol, octanoyl hydroxamate propylene glycol and 1, 2-hexanediol;
the stabilizer is disodium ethylenediamine tetraacetate.
In a second aspect, the present application also provides a method for preparing the above composition, comprising the steps of:
s1, weighing allantoin, a stabilizer, a thickener and a humectant, and uniformly mixing to obtain a material A;
s2, adding hydrolyzed hyaluronic acid and sodium hyaluronate into the material A in the step S1, and uniformly mixing to obtain a material B;
s3, adding water and a pH regulator into the material B in the step S2 to adjust the pH value to obtain a material C;
s4, adding the dragon' S blood extract, the fennel myrtle leaf extract, the African nutmeg seed extract, the alteromonas fermentation product extract and the antioxidant into the material C in the step S3, and uniformly mixing to obtain the composition.
In a third aspect, the application also provides application of the composition with anti-inflammatory and anti-aging effects in preparing cosmetics.
Compared with the prior art, the application has the beneficial effects that:
(1) The composition with anti-inflammatory and anti-aging effects can stimulate the expression of anti-inflammatory factors IL-10 and TGF-beta, promote the generation of inflammatory fading medium SPM, reduce sebum secretion and sebaceous gland volume, inhibit inflammatory cascade reaction, simultaneously enable key fibrous networks to be synthesized again (collagen IV, collagen III, fibronectin and integrin 4 molecular synthesis), repair dermis epidermis connection layers, help maintain the optimal skin defense system, strengthen skin barrier function and stimulate skin repair capability, promote keratinocyte renewal, and enable the composition to have remarkable effects of improving skin redness and reducing wrinkles by compounding and combining the kylin extract, the fennel myrtle leaf extract and the African cardamom seed extract which are main effective components. In addition, the sources of the dragon's blood extract, the fennel myrtle leaf extract and the African nutmeg seed extract adopted by the application are all natural plant extract raw materials, so that the safety is high, and the skin dependence can not be generated;
(2) The main functional components are combined with the hydrolyzed hyaluronic acid, the sodium hyaluronate, the alteromonas fermentation product extract and the allantoin, so that the skin redness improving and wrinkle removing performance of the composition can be further improved, the skin sensibility is reduced, and the skin tightening degree is improved.
Drawings
Fig. 1 is a facial view of a test subject for the soothing effect of the composition having anti-inflammatory and anti-aging effects of example 1 of the present application.
Detailed Description
The technical scheme of the application is further described below by referring to examples. It will be apparent that the described embodiments are only some, but not all, embodiments of the application. All other embodiments, which can be made by those skilled in the art based on the embodiments of the application without making any inventive effort, are intended to be within the scope of the application. The methods or operations used in the examples, unless specifically indicated, are conventional methods or conventional operations in the art.
Examples 1 to 14 and comparative examples 1 to 15
The components and parts by weight of the compositions having anti-inflammatory and anti-aging effects of examples 1 to 14 and comparative examples 1 to 15 are shown in tables 1 and 2 below, and the units are: parts by weight. The total weight of the compositions of examples 1 to 14 and comparative examples 1 to 15 was 100 parts, and the balance was water.
TABLE 1
TABLE 2
The specific components of the thickener, humectant, antioxidant and stabilizer in the compositions of example 1 and examples 11 to 14 of the present application and parts by weight thereof are shown in the following table 3, and the units are: parts by weight. The specific components of the thickener, humectant, antioxidant and stabilizer in the compositions of examples 2 to 10 and comparative examples 1 to 15 of the present application were the same as in example 1.
TABLE 3 Table 3
The preparation method of the compositions of examples 1 to 14 and comparative examples 1 to 15 of the present application comprises the steps of:
s1, weighing allantoin, a stabilizer, a thickener and a humectant, stirring for 3min, and uniformly mixing to obtain a material A;
s2, adding hydrolyzed hyaluronic acid and sodium hyaluronate into the material A in the step S1, and uniformly mixing to obtain a material B;
s3, adding a pH regulator into the material B in the step S2 to regulate the pH value to obtain a material C;
s4, adding the dragon' S blood extract, the fennel myrtle leaf extract, the African nutmeg seed extract, the alteromonas fermentation product extract and the antioxidant into the material C in the step S3, stirring for 10min, uniformly mixing, sampling, detecting, filtering after passing, and discharging to obtain the composition.
Effect example 1
Physicochemical property tests were performed on the compositions having anti-inflammatory and anti-aging effects of the present examples 1 to 14 and comparative examples 1 to 15:
(1) pH value test: directly testing the pH value of the sample;
(2) Heat resistance test: preserving the test sample at 45 ℃ for 3 months, and observing the appearance of the test sample after the test sample is restored to room temperature;
(3) Cold resistance test: preserving the test sample at-10 ℃ for 3 months, and observing the appearance of the test sample after the test sample is restored to room temperature;
(4) And (3) testing the cycle performance: the test samples were stored at-10℃and-5℃and 45℃for 6 hours (one cycle period per day) for a total of 3 months, and the appearance of the test samples was observed after the room temperature was restored.
The test results are shown in table 4 below.
TABLE 4 Table 4
As can be seen from Table 4, the compositions of examples 1 to 14 of the present application are weakly acidic, have a yellowish appearance, are free from abnormal phenomena under low and high temperature environments, and have good cold resistance and heat resistance, and good stability; the compositions of comparative examples 1 to 15 were tested at low temperature or high temperature, and some samples showed a phenomenon of thinning, darkening or delamination, indicating poor cold resistance, heat resistance and cycle stability.
Effect example 2
The anti-inflammatory property test was performed on the compositions having anti-inflammatory and anti-aging effects of examples 1 to 14 and comparative examples 1 to 15 of the present application.
The testing method comprises the following steps: and (5) testing the relieving effect.
Test instrument: visioface1000D facial image analyzer and MPA580 skin tester.
Test object: age range: 10 healthy subjects per group of test cases, 20-50 years old. (healthy men and women are defined as those who do not have chronic disease or major disease or allergic constitution, and who do not take any drugs at present).
Test part: the inner side of the double arms.
Test environment: temperature: 20-22 ℃, humidity: 40-60%, and the test is carried out in a closed space without being directly irradiated by sunlight and an air conditioner air outlet on the test site.
The testing method comprises the following steps: the tested part is the inner side of the double arms, any product (cosmetics or external medicines) cannot be used 2 to 3 days before testing, and water cannot be contacted for 1 to 3 hours. Before the test, the subjects need to uniformly clean the inner sides of the arms and wipe the inner sides with a chipless water-absorbing dry paper towel. Spot-mapping experiments: the test subjects were allowed to sit still for 30min in a constant temperature and humidity environment (temperature 20-22 ℃ C., humidity 40-60%) 0 day before the start of the experiment, and three square areas with 8mm sides were marked at corresponding positions on the inner sides of the left and right forearms, respectively, with 3cm spacing between the three areas. The control area and the sample smearing area are symmetrically distributed on the left arm and the right arm. The skin surface pH (pH), skin transepidermal water loss (TEWL), skin heme (red pigment) content, and skin image acquisition and analysis were tested in the area demarcated inside the left and right hand forearms.
0.2+ -0.01 mL of 1% sodium dodecyl sulfate solution was injected into the plaque chamber, and the filter paper sheet was infiltrated. Then the patch is applied to the inner sides of left and right forearms of a subject, 3 pieces of patch testers are respectively left and right, the spacing between the edges of the cells of the adjacent patch testers is not less than 3cm, and the patch testers are uniformly applied to the skin by lightly pressing the palm, and the erythema is induced for 24 hours. After 24 hours of patch, the patch tester on the arm is removed, after 6 hours, skin parameter values of the patch parts of the left and right forearms are measured, wherein the skin parameter values comprise the pH value (pH value) of the skin surface, the water loss quantity (TEWL value) of the skin through epidermis, the content of skin heme (red pigment) and the skin image acquisition and analysis, and the data are recorded as 6 hours.
Measurement results: within test days 1-12, the test subjects used the samples according to the instructions of the samples, and the application of the samples was required to completely cover each measurement area. The skin parameter values of the forearm patch parts of the left and right hands are measured on the 6 th day and the 12 th day after the test sample is used, and the skin parameter values comprise the pH value (pH value) of the skin surface, the water loss quantity (TEWL value) of the skin through epidermis, the content of skin heme (red pigment) and the skin image acquisition and analysis. Average values were taken and the data were recorded as 6d and 12d.
The test results are shown in tables 5 and 6 below.
TABLE 5
TABLE 6
As can be seen from tables 5 and 6, the compositions of examples 1 to 14 according to the present application can significantly reduce the TEWL value of damaged skin, restore the initial state of skin, and maintain the pH value of the skin surface stable. Meanwhile, according to erythema induced by a patch removal test, the compositions of the embodiments 1 to 14 of the application can effectively reduce the skin haematochrome content, repair damaged skin, and have remarkable effects of relaxing and relieving inflammation. The blank control area only slightly recovers after 12 days, which indicates that the composition has the effects of relaxing and anti-inflammatory and can effectively stabilize the skin.
As can be seen from the comparison between the example 10 and the comparative examples 1-11, the lack of one or more of the extract of kylin, the extract of the leaf of fennel, the extract of African nutmeg seed, the hydrolyzed hyaluronic acid, sodium hyaluronate, the fermentation product of alternate unicellular bacteria and allantoin in the formulation of the emulsion can improve the TEWL value and the content of red pigment of the emulsion at day 28 to different extents, so that the relieving and repairing performance of the emulsion is reduced, and the pH value stability of the emulsion is reduced, so that the stability of the emulsion on the skin surface is further reduced.
As can be seen from the comparison of example 10 and comparative examples 12 to 15, the use of more or less effective components in the formulation of the emulsion affects the synergistic effect between the components, thereby reducing the soothing and repairing properties of the emulsion.
In addition, the present application photographs the skin of a subject employing the sample of example 1 using a VisioFace1000D facial image analyzer magnification, the results of which are shown in fig. 1 below. In fig. 1, image 1 shows the initial state of the skin, image 2 shows 6 hours (no sample) after the patch is damaged, image 3 shows 6 days of sample application, and image 4 shows 12 days of sample application.
From the analysis of fig. 1, it can be seen that after 12 days of application of the product to the sample area, the erythema desquamation of the skin gradually disappeared and the skin barrier recovered faster. Whereas the skin barrier recovery was slower without the use of the product in the placebo area. The application shows that the skin-soothing and brightening skin-improving cream can repair damaged skin and has excellent whitening effect.
Effect example 3
The anti-aging property test was performed on the compositions having anti-inflammatory and anti-aging effects of examples 1 to 14 and comparative examples 1 to 15 of the present application.
Preparation before testing: the tested part is the face. Any product (cosmetic or topical medicine) cannot be used 2-3 days before testing the tested part, and water cannot be contacted for 1-3 hours. Before the test, the subjects need to clean the face uniformly and wipe the face clean with a chipless absorbent dry paper towel.
The testing method comprises the following steps:
(1) After the subject was allowed to sit still in a constant temperature and humidity environment (temperature: 20.+ -. 22 ℃ C., humidity: 40.+ -. 60%) for 30 minutes, the instrument was calibrated according to the facial image analyzer VisioFace1000D instructions. Prior to use of the product, facial skin images of the subjects were first acquired, followed by data analysis of facial skin (fish tail line) wrinkle volume, wrinkle area, and wrinkle area ratio, which were recorded as 0D.
(2) Within days 1-28 of the test, the test subjects used the samples according to the instructions of the sample application, and the application of the samples was required to completely cover each measurement area.
(3) Facial (fish tail) skin parameter values including skin image acquisition, skin wrinkle volume, skin wrinkle area, and skin wrinkle area ratio analysis were measured on day 14, 28, respectively, after use of the test samples. The data are recorded as 14D, 28D.
The test results are shown in table 7 below.
TABLE 7
As can be seen from Table 7, the emulsions of examples 1 to 14 of the present application had the best wrinkle-removing and anti-aging properties on day 28, among them the emulsion of example 10 had the best wrinkle-removing and anti-aging properties on day 28.
As can be seen from comparing example 10 with comparative examples 1-11, the lack of one or more of kylin extract, fennel myrtle leaf extract, african nutmeg seed extract, hydrolyzed hyaluronic acid, sodium hyaluronate, alternate unicellular fungus fermentation product, allantoin in the formulation of the emulsion resulted in various degrees of reduction in the wrinkle volume, wrinkle area, and wrinkle area ratio of the emulsion, resulting in reduced anti-aging performance of the emulsion.
As can be seen from the comparison of the example 10 and the comparative examples 12 to 15, the use of more or less effective components in the formulation of the emulsion affects the synergistic effect of the components, thereby reducing the wrinkle-removing and anti-aging properties of the emulsion.
Finally, it should be noted that the above embodiments are only for illustrating the technical solution of the present application and not for limiting the scope of the present application, and although the present application has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present application may be modified or substituted equally without departing from the spirit and scope of the technical solution of the present application.
Claims (10)
1. The composition with anti-inflammatory and anti-aging effects is characterized by comprising the following components in parts by weight: 0.0005-0.015 part of dragon's blood extract, 0.0005-0.01 part of fennel myrtle leaf extract and 0.0004-0.008 part of african cardamom seed extract.
2. The composition of claim 1, comprising the following components in parts by weight: 0.007-0.013 part of dragon's blood extract, 0.005-0.008 part of fennel myrtle leaf extract and 0.0012-0.0028 part of African cardamom seed extract.
3. The composition of claim 1, further comprising the following components in parts by weight: 0.01-1 part of hydrolyzed hyaluronic acid, 0.03-0.09 part of sodium hyaluronate, 0.0006-0.003 part of alteromonas fermentation product extract and 0.1-0.3 part of allantoin.
4. A composition according to claim 3, comprising the following components in parts by weight: 0.007-0.013 part of dragon's blood extract, 0.005-0.008 part of fennel myrtle leaf extract, 0.0012-0.0028 part of African cardamom seed extract, 0.3-0.8 part of hydrolyzed hyaluronic acid, 0.04-0.08 part of sodium hyaluronate, 0.0015-0.0024 part of alteromonas fermentation product extract and 0.15-0.25 part of allantoin.
5. The composition of claim 4, comprising the following components in parts by weight: 0.01 part of dragon's blood extract, 0.007 part of fennel myrtle leaf extract, 0.002 part of African cardamom seed extract, 0.5 part of hydrolyzed hyaluronic acid, 0.06 part of sodium hyaluronate, 0.0021 part of alteromonas fermentation product extract and 0.2 part of allantoin.
6. The composition of any one of claims 3 to 5, further comprising the following components in parts by weight: 0.25-1.8 parts of thickener, 2.6686-25.472 parts of humectant, 0.591-4.005 parts of antioxidant and 0.01-1 part of stabilizer; the stabilizer is disodium ethylenediamine tetraacetate; the composition further comprises water and a pH adjuster.
7. The composition of claim 6, wherein the thickener is 0.5 to 1.1 parts by weight, the humectant is 6.9288 to 12.1152 parts by weight, the antioxidant is 1.323 to 2.289 parts by weight, and the stabilizer is 0.03 to 0.07 parts by weight.
8. The composition of claim 6, wherein the thickener is selected from at least one of acrylates/C10-30 alkanol acrylate cross-linked polymers, sodium acrylate copolymers, lecithin; the humectant is at least one of glycerolyether-26, glycerin, butanediol and ethylhexyl glycerin; the antioxidant is at least one selected from p-hydroxyacetophenone, propylene glycol, octanoyl hydroxamate propylene glycol and 1, 2-hexanediol.
9. A method of preparing the composition of claim 6, comprising the steps of:
s1, weighing allantoin, a stabilizer, a thickener and a humectant, and uniformly mixing to obtain a material A;
s2, adding hydrolyzed hyaluronic acid and sodium hyaluronate into the material A in the step S1, and uniformly mixing to obtain a material B;
s3, adding water and a pH regulator into the material B in the step S2 to adjust the pH value to obtain a material C;
s4, adding the dragon' S blood extract, the fennel myrtle leaf extract, the African nutmeg seed extract, the alteromonas fermentation product extract and the antioxidant into the material C in the step S3, and uniformly mixing to obtain the composition.
10. The use of a composition with anti-inflammatory and anti-aging effects according to any one of claims 1 to 8 in the preparation of cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310196679.5A CN116139060B (en) | 2023-03-02 | 2023-03-02 | Composition with anti-inflammatory and anti-aging effects and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310196679.5A CN116139060B (en) | 2023-03-02 | 2023-03-02 | Composition with anti-inflammatory and anti-aging effects and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116139060A CN116139060A (en) | 2023-05-23 |
| CN116139060B true CN116139060B (en) | 2023-10-31 |
Family
ID=86350564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310196679.5A Active CN116139060B (en) | 2023-03-02 | 2023-03-02 | Composition with anti-inflammatory and anti-aging effects and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116139060B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050114309A (en) * | 2004-06-01 | 2005-12-06 | 한불화장품주식회사 | Cosmetic composition containing draconis sanguis extract |
| CN101282711A (en) * | 2005-10-04 | 2008-10-08 | Lvmh研究公司 | Cosmetic compositions in particular with anti-aging activity comprising an extract of aframomum angustifolium or longoza plant |
| CN106456530A (en) * | 2014-05-16 | 2017-02-22 | 雷斯托尔西有限公司 | Biphasic cosmetic |
| CN115317427A (en) * | 2022-09-13 | 2022-11-11 | 广州市涵美化妆品有限公司 | Anti-inflammatory repairing composition and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3077204B1 (en) * | 2018-01-30 | 2021-09-17 | Isp Investments Llc | MYRCIARIA DUBIA FRUIT EXTRACTS RICH IN ORGANIC ACIDS, COSMETIC COMPOSITIONS CONTAINING IT AND THEIR COSMETIC USES |
-
2023
- 2023-03-02 CN CN202310196679.5A patent/CN116139060B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050114309A (en) * | 2004-06-01 | 2005-12-06 | 한불화장품주식회사 | Cosmetic composition containing draconis sanguis extract |
| CN101282711A (en) * | 2005-10-04 | 2008-10-08 | Lvmh研究公司 | Cosmetic compositions in particular with anti-aging activity comprising an extract of aframomum angustifolium or longoza plant |
| CN106456530A (en) * | 2014-05-16 | 2017-02-22 | 雷斯托尔西有限公司 | Biphasic cosmetic |
| CN115317427A (en) * | 2022-09-13 | 2022-11-11 | 广州市涵美化妆品有限公司 | Anti-inflammatory repairing composition and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116139060A (en) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110652481B (en) | Hyaluronic acid mild moisturizing facial cleanser and preparation method thereof | |
| CN110123695B (en) | Cell energy restoration composition | |
| CN110664644B (en) | Skin care composition containing folic acid, essence and preparation method thereof | |
| CN111329802A (en) | Skin moisturizing lotion and preparation method thereof | |
| WO2024045952A1 (en) | Recombinant collagen-containing composition having effects of repairing and soothing, eye cream containing same, preparation method therefor, and use thereof | |
| CN112842985A (en) | Moisturizing and repairing composition | |
| CN112168766A (en) | Anti-inflammatory and relieving aloe gel and preparation method thereof | |
| CN111643427A (en) | Anti-aging composition, anti-aging cosmetic and preparation method thereof | |
| CN115400065A (en) | Skin care composition with multiple effects of moisturizing, resisting wrinkles, resisting aging, relieving and repairing and application thereof | |
| CN108771643B (en) | Nourishing and moistening repair essence | |
| CN114306165A (en) | Moisturizing composition and preparation method thereof | |
| CN108852976B (en) | Crystal moistening nourishing lotion | |
| CN112641657B (en) | Moisturizing and repairing face cream and preparation method thereof | |
| CN117398326A (en) | Skin moisturizing and repairing composition and application thereof | |
| CN117243844A (en) | Collagen-containing skin care product essence and preparation method and application thereof | |
| CN111265442A (en) | Skin care composition and application thereof | |
| CN116139060B (en) | Composition with anti-inflammatory and anti-aging effects and preparation method and application thereof | |
| CN111012699A (en) | Antioxidant oil-controlling emulsion containing fucoidan-kelp extract | |
| CN115919686A (en) | Skin soothing lotion for enhancing skin barrier and preparation method thereof | |
| CN114903810A (en) | Anti-wrinkle composition containing peptide and application thereof | |
| CN108852977B (en) | Crystal moistening essence | |
| CN114272190A (en) | Composition containing aloe active compound and preparation method and application thereof | |
| CN113576994A (en) | Composition with synergistic moisturizing and relieving effects, cosmetic and preparation method thereof | |
| CN112057407A (en) | Face cream and preparation method thereof | |
| CN111419732A (en) | Protective composition and application thereof in indoor protective cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |